Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline

Informations projet

RespiriNTM

N° de convention de subvention: 853932

DOI

10.3030/853932

Date de signature de la CE 8 Mai 2019

Date de début 1 Mai 2019

Date de fin 30 Avril 2027

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 16 009 225,82

Contribution de l’UE

€ 5 687 983,75

Coordonné par

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (9)

In vitro activity of single HDT compounds report

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular NTM strains in human cells

Zebrafish in vivo test report

The Zebrafish in vivo test report will summarize the methodology and results of the efficacy against known tuberculosis compounds and the effect on granuloma testing in zebrafish larvae for individual NTM compounds

HDT response report

We will test at least one candidate HDT compound supplied by the other partners.

Development of a chronic infection mice model to study NTM infections

A model of persistent infection would be precious to improve the tools enabling the discovery of new antibiotic regimens against NTM in the frame of the project as well as in further studies.

Human NTM in vitro infection Model report

The Human NTM in vitro infection Model report will describe the methodology and assay conditions for an in vitro infection model for NTM (M. avium) in human cells

Purified NTM cytochrome report

The Purified NTM cytochrome report will describe the methodology and confirmation of the biological structures of the purified cytochrome bc1, bc1:aa3, and bd

NTM drug PK report

NTM drug PK report will describe the methodology used and describe the PK model of the NTM drugs

HDT target Identification and mode of action report

The HDT target Identification and mode of action report will describe the process, the methodology and summarize the identified of targets and mode of actions of lead HDT compounds.

Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report

The Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report will describe the assay, conditions and characterisation methodology of the enzymatic assay for testing cytochrome bc1 and cytochrome bd inhibitors

Websites, patent fillings, videos etc. (1)

Website RESPIRI- NTM online

The website developped for communication of all RespiriNTM activities will be active and online

Publications

Peer reviewed articles (5)

Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria

Auteurs: Wanbin Hu, Bjørn E. V. Koch, Gerda E. M. Lamers, Gabriel Forn-Cuní, Herman P. Spaink
Publié dans: Frontiers in Immunology, 2023, ISSN 1664-3224
Éditeur: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1075473

Modeling nontuberculous mycobacterial infections in zebrafish

Auteurs: Matt D. Johansen Herman P. Spaink Stefan H. Oehlers Laurent Kremer
Publié dans: Trends in Microbiology, 2023, ISSN 1878-4380
Éditeur: Cell Press
DOI: 10.1016/j.tim.2023.11.011

Host- directed therapy to combat mycobacterial infections

Auteurs: Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Publié dans: Immunological Reviews, Numéro Volume 301, Numéro 1, 25-May-2021, 2021, Page(s) 62-83, ISSN 0105-2896
Éditeur: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951

Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium

Auteurs: Gül Kilinç, Kimberley V. Walburg, Kees L. M. C. Franken, Merel L. Valkenburg, Alexandra Aubry, Mariëlle C. Haks, Anno Saris1, Tom H. M. Ottenhoff
Publié dans: Frontiers in Cellular and Infection Microbiology, 2022, ISSN 2235-2988
Éditeur: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.872361

Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy

Auteurs: Gül Kilinç, Ralf Boland, Matthias T. Heemskerk, Herman P. Spaink, Mariëlle C. Haks, Michiel van der Vaart, Tom H. M. Ottenhoff, Annemarie H. Meijer, Anno Saris
Publié dans: Microbiology Spectrum, Numéro 12, 2024, ISSN 2165-0497
Éditeur: American Society for Microbiology
DOI: 10.1128/spectrum.00167-24